Effect of different gonadotrophin priming on IVM of oocytes from women with normal ovaries: a prospective randomized study.
This study was designed to determine if the efficiency of in-vitro maturation (IVM) in women with normal ovaries can be improved by gonadotrophin administration. 400 women were randomly allocated in four groups: group A, non-primed cycles; group B, human chorionic gonadotrophin (HCG)-primed cycles; group C, FSH-primed cycles; and group D, FSH- plus HCG-primed cycles. There were significant differences in the IVM rate among the groups. In groups where HCG was used, the overall maturation rate was higher (57.9% in group B and 77.4% in group D; 48.4% in group A and 50.8% in group C) and the percentage of total available metaphase II-stage oocytes was higher (60.4% in group B and 82.1% in group D; 48.4% in group A and 50.8% in group C). The overall clinical pregnancy rate per transfer (CPR) was 18.3% and the implantation rate (IR) was 10.6%. There was a difference in CPR among the groups: group D (29.9%) versus group A (15.3%), P = 0.023; group D versus group B (7.6%), P < 0.0001; group D versus group C (17.3%), P = 0.046. The results of this study are clearly in favour of FSH plus HCG priming. FSH priming and HCG priming alone showed no significant effects on clinical outcome.
Biogenesi Reproductive Medicine Centre, Istituti Clinici Zucchi, V Zucchi, 24-Monza, Italy.
R
R
Fadini
M B
MB
Dal Canto
M
M
Mignini Renzini
F
F
Brambillasca
R
R
Comi
D
D
Fumagalli
M
M
Lain
M
M
Merola
R
R
Milani
E
E
De Ponti
D000328:Adult; D002478:Cells, Cultured; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004338:Drug Combinations; D010064:Embryo Implantation / Q000187:drug effects / Q000502:physiology; D004624:Embryo Transfer; D047108:Embryonic Development / Q000187:drug effects; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage; D006062:Gonadotropins / Q000008:administration & dosage*; D006262:Health; D006801:Humans; D009865:Oocytes / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D009866:Oogenesis / Q000187:drug effects* / Q000502:physiology; D010053:Ovary / Q000187:drug effects* / Q000502:physiology; D011247:Pregnancy; D018873:Pregnancy Rate
D006063:Chorionic Gonadotropin; D004338:Drug Combinations; D005300:Fertility Agents, Female; D006062:Gonadotropins; D005640:Follicle Stimulating Hormone